{"id":4274,"date":"2025-08-04T17:03:02","date_gmt":"2025-08-04T14:03:02","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4274"},"modified":"2025-08-04T17:13:24","modified_gmt":"2025-08-04T14:13:24","slug":"dyne-therapeutics-announces-fda-breakthrough-therapy-designation-for-dyne-251-in-duchenne-muscular-dystrophy-dmd","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/es\/dyne-therapeutics-announces-fda-breakthrough-therapy-designation-for-dyne-251-in-duchenne-muscular-dystrophy-dmd\/","title":{"rendered":"Dyne Therapeutics anuncia la designaci\u00f3n de terapia innovadora para FDA en la distrofia muscular de Duchenne (DMD)"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Dyne Therapeutics anunci\u00f3 que la Administraci\u00f3n de Alimentos y Medicamentos de los Estados Unidos (FDA) (FDA) otorg\u00f3 la designaci\u00f3n de terapia innovadora a DYNE-251 para el tratamiento de pacientes con distrofia muscular de Duchenne (DMD), susceptibles a la omisi\u00f3n del ex\u00f3n 51. Esta designaci\u00f3n se basa en datos del ensayo cl\u00ednico DELIVER, actualmente en curso.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">DYNE-251: Designaci\u00f3n de terapia innovadora<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cEsta designaci\u00f3n de Terapia Innovadora para DYNE-251 demuestra su potencial como terapia de \u00faltima generaci\u00f3n, dise\u00f1ada para brindar una mejora funcional significativa a las personas con DMD, en quienes la omisi\u00f3n del ex\u00f3n 51 puede conducir a la producci\u00f3n de distrofina casi completa\u201d, afirm\u00f3 el Dr. Doug Kerr, Ph.D., director m\u00e9dico de Dyne. \u201cComo ya hemos revelado, DYNE-251 ha demostrado una mejora funcional sostenida durante dieciocho meses, seg\u00fan par\u00e1metros clave como el tiempo para levantarse y la velocidad de zancada en el percentil 95. El nivel de expresi\u00f3n de distrofina casi completa observado representa un avance significativo que podr\u00eda brindar beneficios significativos a los pacientes\u201d.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>M\u00e1s informaci\u00f3n<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/es\/exon-51-skipping-therapies-dmd\/\" target=\"_blank\" rel=\"noreferrer noopener\">Pr\u00f3ximas terapias de omisi\u00f3n del ex\u00f3n 51 para el tratamiento de la distrofia muscular de Duchenne<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Leer m\u00e1s<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/es\/dyne-therapeutics-receives-european-medicines-agency-ema-orphan-drug-designation-for-dyne-251-in-duchenne-muscular-dystrophy\/\">Dyne Therapeutics recibe la designaci\u00f3n de medicamento hu\u00e9rfano de la Agencia Europea de Medicamentos (EMA) para DYNE-251 en la distrofia muscular de Duchenne.<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Dyne Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to DYNE-251 for the treatment of patients with Duchenne muscular dystrophy (DMD), amenable to exon 51 skipping. The designation is based on data from the ongoing DELIVER clinical trial. DYNE-251: Breakthrough Therapy Designation \u201cThis Breakthrough Therapy Designation for DYNE-251 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4275,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[208,145,122,193,194,88],"class_list":["post-4274","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-dyne-therapeutics","tag-dyne-251","tag-exon-51","tag-exon-51-skipping","tag-exon-51-treatment","tag-fda"],"subtitle":"To treat Duchenne muscular dystrophy (DMD) patients who can skip exon 51, Dyne Therapeutics announced that the FDA has given Breakthrough Therapy Designation to DYNE-251. From the ongoing DELIVER clinical trial, the designation was made.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/4274","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/comments?post=4274"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/4274\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media\/4275"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media?parent=4274"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/categories?post=4274"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/tags?post=4274"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}